mCRC patients who are administered regimens with anti-EGFR mAbs have an approximately 1.5-fold increased risk of experiencing venous or pulmonary embolism compared to those not treated with anti-EGFR mAbs20. This evidence concerns the gene EGFR and pulmonary embolism.